Please login to the form below

Not currently logged in
Email:
Password:

transplants

This page shows the latest transplants news and features for those working in and with pharma, biotech and healthcare.

Triplet approvals for myeloma boost Celgene in Q2

Triplet approvals for myeloma boost Celgene in Q2

transplant, with Pomalyst cleared with the same two drugs for second-line use.

Latest news

More from news
Approximately 8 fully matching, plus 222 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Its only immediate competition will be donor stem cell transplants, which carry significant patient risks. ... LentiGlobin provides an allogeneic alternative to autologous transplants. Instead of using donor cells, the patient’s own cells are harvested,

  • The Orkambi blame game The Orkambi blame game

    By contrast, Leiden claimed Vertex merely wanted NICE to factor in more direct savings to healthcare costs – such as greatly reduced hospitalisation and the need for lung transplants.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    That said, for thalassemia, and for sickle cell, we believe these are potentially one-time curative treatments, because these stem cell transplants have been shown to last a very long time, ... Conventional stem cell transplants cost anywhere between $500

  • Health on instalment Health on instalment

    Distasteful but…. In addition to pay-for-performance, other possible funding strategies under consideration include mandatory price limits; re-insurance (currently used for expensive transplant operations); risk pooling; and lease-like

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics